These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20714371)

  • 1. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.
    Dalal AA; St Charles M; Petersen HV; Roberts MH; Blanchette CM; Manavi-Zieverink K
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():179-87. PubMed ID: 20714371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
    Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
    Chatterjee A; Shah M; D'Souza AO; Bechtel B; Crater G; Dalal AA
    Respir Res; 2012 Feb; 13(1):15. PubMed ID: 22340019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA; Candrilli SD; Davis KL
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD.
    Dalal AA; Shah MB; D'Souza AO; Lunacsek OE; Nagar SP; Crater GD
    Respir Res; 2012 May; 13(1):41. PubMed ID: 22651541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.
    Yawn BP; Raphiou I; Hurley JS; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2010 Jun; 5():165-78. PubMed ID: 20631816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
    Delea TE; Hagiwara M; Dalal AA; Stanford RH; Blanchette CM
    Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.
    Keating GM; McCormack PL
    Drugs; 2007; 67(16):2383-405. PubMed ID: 17983257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
    Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.
    Anzueto A; Ferguson GT; Feldman G; Chinsky K; Seibert A; Emmett A; Knobil K; O'Dell D; Kalberg C; Crater G
    COPD; 2009 Oct; 6(5):320-9. PubMed ID: 19863361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
    Fenton C; Keating GM
    Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
    Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
    Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
    Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
    Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
    Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population.
    Dalal AA; Shah M; D'Souza AO; Chaudhari S; Crater G
    Int J Chron Obstruct Pulmon Dis; 2012; 7():11-9. PubMed ID: 22315518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.